BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA

Key Points

• BlackRock acquired 12.49 million Savara shares worth approximately $76.97 million, representing about 6.1% of the company. Institutional investors collectively own 87.93% of SVRA.
• Savara reported a quarterly loss of $0.16 per share, missing the consensus estimate of a $0.14 loss; analysts expect a full-year loss of $0.62 per share.
• SVRA has a “Moderate Buy” consensus rating and an average price target of $10.14, despite recent sell ratings and the stock opening at $5.26.

BlackRock Inc. acquired a new position in Savara Inc. (NASDAQ:SVRA - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,494,498 shares of the company's stock, valued at approximately $76,966,000. BlackRock Inc. owned approximately 6.10% of Savara at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. VR Adviser LLC raised its stake in Savara by 8.4% during the fourth quarter. VR Adviser LLC now owns 13,740,375 shares of the company's stock valued at $82,854,000 after buying an additional 1,059,332 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Savara by 20.8% in the 4th quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company's stock worth $60,551,000 after buying an additional 1,728,453 shares during the last quarter. Nantahala Capital Management LLC boosted its position in Savara by 5.4% in the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company's stock worth $31,328,000 after purchasing an additional 450,000 shares during the last quarter. Polar Capital Holdings Plc purchased a new position in shares of Savara in the fourth quarter worth approximately $50,086,000. Finally, RTW Investments LP bought a new stake in Savara during the fourth quarter valued at about $35,893,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Price Performance

Shares of SVRA opened at $5.26 on Monday. The company has a 50 day moving average of $5.70 and a two-hundred day moving average of $5.48. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. Savara Inc. has a twelve month low of $3.19 and a twelve month high of $7.01. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -9.07 and a beta of 0.29.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). As a group, analysts predict that Savara Inc. will post -0.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SVRA. Wall Street Zen cut shares of Savara from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Savara has an average rating of "Moderate Buy" and an average target price of $10.14.

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source